User menu

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Bibliographic reference Dimopoulos, Meletios A ; Moreau, Philippe ; Palumbo, Antonio ; Joshua, Douglas ; Pour, Ludek ; et. al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.. In: The Lancet Oncology, Vol. 17, no.1, p. 27-38 (2016)
Permanent URL http://hdl.handle.net/2078.1/177465